Ziopharm Oncology (ZIOP) soars 10.3% after saying its palifosfamide (ZIO-201) treatment...

|By:, SA News Editor

Ziopharm Oncology (ZIOP) soars 10.3% after saying its palifosfamide (ZIO-201) treatment performed well in patients with metastatic soft tissue sarcoma in a Phase III trial, with the drug reaching its target number for progression-free survival. The company will release full results in March. (PR)